Serum HE4 and polymorphisms in MMP9 and MMP13 associated with survival outcome in patients with endometrial carcinoma: a retrospective cohort study and nomogram development

AIMS: Endometrial cancer (EC) is the most common gynecologic malignancy. Identifying prognostic biomarkers can improve outcome prediction and risk stratification. PATIENTS AND METHODS: This study evaluated the prognostic value of serum human epididymis protein 4 (HE4) levels and matrix metalloproteinase (MMP)9/MMP13 gene polymorphisms in EC. A total of 232 surgical EC patients (Jan 2021-Oct 2022) were analyzed. Progression-free survival (PFS) and overall survival (OS) were assessed. RESULTS: = 0.001). The area under the receiver operating characteristic curve (AUC) for the three-year PFS prediction model was 0.935 (95% confidence interval [CI]: 0.891-0.978), and that for the OS model was 0.914 (95% CI: 0.845-0.983). CONCLUSIONS: HE4 is a valuable biomarker associated with three-year survival in EC. The phenotypes of MMP9 R279Q and MMP13 rs2252070 may also be associated with three-year PFS.